טוען...
HIV-1 Integrase Inhibitors That Are Active against Drug-Resistant Integrase Mutants
The currently recommended first-line therapy for HIV-1-infected patients is an integrase (IN) strand transfer inhibitor (INSTI), either dolutegravir (DTG) or bictegravir (BIC), in combination with two nucleoside reverse transcriptase inhibitors (NRTIs). Both DTG and BIC potently inhibit most INSTI-r...
שמור ב:
| הוצא לאור ב: | Antimicrob Agents Chemother |
|---|---|
| Main Authors: | , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
American Society for Microbiology
2020
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7449158/ https://ncbi.nlm.nih.gov/pubmed/32601157 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00611-20 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|